

LC BEAD™ Embolization

**PROVEN.
PREDICTABLE.
REPRODUCIBLE.¹**





PROVEN. PREDICTABLE. REPRODUCIBLE.¹

LC Bead is a controlled embolization system intended for the purpose of embolising the blood vessels of a variety of hypervascularized tumors and arteriovenous malformations. LC Bead is a preformed, deformable microsphere consisting of a biocompatible, sulphonate-modified, N-Fil hydrogel.

Pre LC Bead treatment



Post LC Bead treatment



Images © Wolters Kluwer Health, Inc. Reproduced with permission from: Reyes DK, Vossen JA, Kamel IR et al. Cancer Journal 2009; 15(6): 526-32

LC Bead features:

- Calibrated size to ensure predictable embolization¹
- Compressible design for smooth catheter delivery¹
- Compatible with a large range of microcatheters¹
- Blue tinted beads for enhanced visualization¹
- Spherical shape for optimal control and delivery¹

LC Bead may allow for the following benefits:

- Standardization of technique for predictable and consistent results¹
- Controlled embolization¹
- Reproducible outcomes¹
- Embolization of a broad range of hypervascularised tumours¹

Ordering Information

	LC BeadM1	LC Bead	
Size	70-150 µm	100-300 µm	300-500 µm
Label Color	Black and yellow	Yellow	Blue
Volume of Beads	2 ml	2 ml	2 ml
Product Code	VE020GS	VE220GS	VE420GS

Reference: 1. Biocompatibles data on file.



CORPMEDICAL CHILE LIMITADA

Representante exclusivo en Chile

La Concepción 191, of. 205, Providencia, Santiago.

Teléfono: +56224816820 / Celular: +56992359435

Email: corpmedical@corpmedical.cl

www.corpmedical.cl / www.grupocorpmedicalchile.com



LC BEAD

INDICATIONS: LC Bead microspheres are intended to be used for the embolisation of hypervascular tumors and arteriovenous malformations (AVMs). **CONTRAINDICATIONS:** 1. Patients intolerant to occlusion procedures. 2. Vascular anatomy or blood flow that precludes catheter placement or emboli injection. 3. Presence or likely onset of vasospasm. 4. Presence or likely onset of hemorrhage. 5. Presence of severe atheromatous disease. 6. Presence of feeding arteries smaller than distal branches from which they emerge. 7. Presence of patent extra-to-intracranial anastomoses or shunts. 8. Presence of collateral vessel pathways potentially endangering normal territories during embolisation. 9. Presence of end arteries leading directly to cranial nerves. 10. Presence of arteries supplying the lesion not large enough to accept LC Bead microspheres. 11. Vascular resistance peripheral to the feeding arteries precluding passage of LC Bead microspheres into the lesion. 12. Do not use LC Bead microspheres in the following applications: i. Embolisation of large diameter arteriovenous shunts (ie. where the blood does not pass through the arterial/capillary/venous transition but directly from artery to vein. ii. The pulmonary arterial vasculature. iii. Any vasculature where the use of LC Bead Embolic Agent could pass directly into the internal carotid artery or other nontarget territories. **WARNING:** Studies have shown that LC Bead microspheres should only be performed by physicians who have received appropriate interventional occlusion training in the region intended to be embolised. Federal (USA) law restricts this device to sale by or on order of a physician.

POTENTIAL COMPLICATIONS: 1. Undesirable reflux or passage of LC Bead microspheres into normal arteries adjacent to the targeted lesion or through the lesion into other arteries or arterial beds, such as the internal carotid artery, pulmonary, or coronary circulations. 2. Pulmonary embolisation. 3. Ischemia at an undesirable location. 4. Capillary bed saturation and tissue damage. 5. Ischaemic stroke or Ischaemic infarction. 6. Vessel or lesion rupture and hemorrhage. 7. Neurological deficits including cranial nerve palsies. 8. Vasospasm. 9. Death. 10. Recanalisation. 11. Foreign body reactions necessitating medical intervention. 12. Infection necessitating medical intervention. 13. Clot formation at the tip of the catheter and subsequent dislodgement.

LC Bead M1

INDICATIONS: LC Bead M1 are intended to be used for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). **CONTRAINDICATIONS:** 1. Patients intolerant to occlusion procedures. 2. Vascular anatomy or blood flow that precludes catheter placement or emboli injection. 3. Presence or likely onset of vasospasm. 4. Presence or likely onset of hemorrhage. 5. Presence of severe atheromatous disease. 6. Presence of feeding arteries smaller than distal branches from which they emerge. 7. Presence of patent extra-to-intracranial anastomoses or shunts. 8. Presence of collateral vessel pathways potentially endangering normal territories during embolization. 9. Presence of end arteries leading directly to cranial nerves. 10. Presence of arteries supplying the lesion not large enough to accept LC Bead M1. 11. Vascular resistance peripheral to the feeding arteries precluding passage of LC Bead M1 into the lesion. 12. Do not use LC Bead M1 in the following applications: i. Embolization of large diameter arteriovenous shunts (ie. where the blood does not pass through the arterial/capillary/venous transition but directly from artery to vein. ii. The pulmonary arterial vasculature. iii. Any vasculature where LC Bead M1 Embolic Agent could pass directly into the internal carotid artery or other nontarget territories. **WARNING:** Studies have shown that LC Bead M1 do not form aggregates and, as a result, penetrate deeper into the vasculature as compared to similarly sized PVA particles. Care must be taken to choose a larger sized LC Bead M1 Embolic Agent when embolizing arteriovenous malformations with large shunts to avoid passage of the microspheres into the pulmonary or coronary circulation. The color of the LC Bead M1 could be visible through the skin if injected into arteries feeding superficial tissues.

CAUTION: Federal (USA) law restricts this device to sale by or on order of a physician. **POTENTIAL COMPLICATIONS:** 1. Undesirable reflux or passage of LC Bead M1 into normal arteries adjacent to the targeted lesion or through the lesion into other arteries or arterial beds, such as the internal carotid artery, pulmonary, or coronary circulations. 2. Non-target embolization. 3. Pulmonary embolization. 4. Ischemia at an undesirable location. 5. Capillary bed saturation and tissue damage. 6. Ischemic stroke or Ischaemic infarction. 7. Vessel or lesion rupture and hemorrhage. 8. Neurological deficits including cranial nerve palsies. 9. Vasospasm. 10. Death. 11. Recanalization. 12. Foreign body reactions necessitating medical intervention. 13. Infection necessitating medical intervention. 14. Clot formation at the tip of the catheter and subsequent dislodgement.

**Boston
Scientific**
Advancing science for life™

Peripheral Interventions
300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

To order product or for more information
contact customer service at 1.888.272.1001.

© 2019 Boston Scientific Corporation
or its affiliates. All rights reserved.

PI-744208-AA